drugset / Trial / NCT00256854

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854

Phase 3 Completed 135 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.

Timeline

Start
2005-11-14
Primary completion
2006-09-21
Completion
2006-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropinirole Small molecule 1 mg
Subject Ropinirole Small molecule 2 mg
Subject Ropinirole Small molecule 3 mg